AUROBINDO PHARMA Q4

Saw good performance across all segments Gross margins supported by product mix and benign raw material prices API growth driven by higher volumes Raw material cost eased further during the quarter Eyeing high single-digit growth through FY26 Expect high single-digit revenue growth in FY26 Confident of maintaining current EBITDA margin levels in FY26